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Abstract
The repressor element silencing transcription factor (REST) is a coordinate transcriptional and epigenetic regulator which
functions as a tumor suppressor or an oncogene depending on cellular context, and a truncated splice variant REST4 has
been linked to various types of cancer. We performed a comprehensive analysis of alternative splicing (AS) of REST by rapid
amplification of cDNA ends and PCR amplification of cDNAs from various tissues and cell lines with specific primers. We
identified 8 novel alternative exons including an alternate last exon which doubles the REST gene boundary, along with
numerous 59/39 splice sites and ends in the constitutive exons. With the combination of various splicing patterns (e.g. exon
skipping and alternative usage of the first and last exons) that are predictive of altered REST activity, at least 45 alternatively
spliced variants of coding and non-coding mRNA were expressed in a species- and cell-type/tissue-specific manner with
individual differences. By examining the repertoire of REST pre-mRNA splicing in 27 patients with kidney, liver and lung
cancer, we found that all patients without exception showed differential expression of various REST splice variants between
paired tumor and adjacent normal tissues, with striking cell-type/tissue and individual differences. Moreover, we revealed
that exon 3 skipping, which causes no frame shift but loss of a domain essential for nuclear translocation, was affected by
pioglitazone, a highly selective activator of the peroxisome proliferator-activated receptor gamma (PPARc) which
contributes to cell differentiation and tumorigenesis besides its metabolic actions. Accordingly, this study demonstrates an
extensive AS of REST pre-mRNA which redefines REST gene boundary and structure, along with a general but differential link
between REST pre-mRNA splicing and various types of cancer. These findings advance our understanding of the complex,
context-dependent regulation of REST gene expression and function, and provide potential biomarkers and therapeutic
targets for cancer.
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Introduction
Alternative splicing (AS), a process to differentially link exons in
a single precursor mRNA (pre-mRNA) to produce two or more
different mature mRNAs, is a major contributor to transcriptome
and proteome diversity, with .90% of human genes undergoing
AS in a tissue- and developmental stage-specific manner [1,2]. It is
now recognized that the coupling between transcription and
splicing is crucial for AS regulation [3,4], and that exon-intron
junctions or splice sites (SS) are specified by epigenetic modifica-
tions dependent on cellular context [4,5]. Accordingly, epigenetic
modifications affect not only transcription, but also the co-
transcriptional splicing [6,7]. Epigenetic regulation of pre-mRNA
splicing, in line with the spatiotemporal selection of SS, suggest
that AS cross-talks with environmental cues to contribute to
adaptive responses and disease pathophysiology. Indeed, AS is
modulated by the circadian clock, psychological stress, and
numerous hormones and chemicals [8–10], while an estimated
15–60% of human genetic diseases, ranging from neurological to
tumorigenic and metabolic disorders, involve splicing mutations
[2,11–14].
The repressor element silencing transcription factor (REST,
also known as NRSF for neuron-restrictive silencing factor),
originally identified as a repressor of neuronal genes in non-
neuronal cells [15,16], is now recognized as a coordinate
transcriptional and epigenetic regulator that orchestrates the
cellular epigenome in both neuronal and non-neuronal cells [17].
REST binds to widely distributed genomic regulatory sequences
including the repressor element-1 (RE1) by a DNA-binding
domain (DBD) which comprises 8 zinc finger motifs (ZFMs),
while its effect on gene expression is mediated by two independent
repression domains (RD1 and RD2) which directly or indirectly
recruit numerous transcriptional and epigenetic cofactors. Briefly,
the N-terminal RD1 recruits mSin3, a scaffold for histone
deacetylases (HDACs), while the C-terminal RD2 partners with
the REST corepressor (CoREST) which additionally recruits
HDACs, methyl-CpG binding protein 2 (MeCP2), histone H3K4
lysine demethylase (LSD1) and H3K9 methyltransferases (G9a), as
well as a component of the SWI/SNF chromatin remodeling
complex-Brg1. By recruiting numerous cofactors to target gene
loci, REST promotes dynamic, context-dependent chromatin
organization and repression/activation of thousands of genes
involved in many cellular processes including tumorigenesis, for
which it functions as a tumor suppressor or an oncogene
depending on cellular context [18,19]. The diverse, context-
dependent function of REST is specified by multiple mechanisms
PLOS ONE | www.plosone.org 1 April 2013 | Volume 8 | Issue 4 | e62217including proteasomal degradation, nuclear translocation and pre-
mRNA splicing [20–23], as well as the modulation by non-coding
RNAs (ncRNAs) and binding affinity of REST to diverse RE1 and
non-RE1 sites [24,25].
REST undergoes AS with a limited number of splice variants
having been reported, of which a C-terminal truncated variant
REST4, which contains RD1 and ZFMs 1–5, has been well
documented [20,21]. As a dominant negative, REST4 is linked to
small cell lung cancer (SCLC), neuroblastoma and breast cancer
[26–28], and it contributes to early-life programming of the stress
response, neuroprotection and hormonal regulation of glutamine
synthethase [29–31]. Another two splice variants, REST1 which
contains RD1 and ZFMs 1–4 [16], and REST-5FD with a deletion
of the ZFM-5 [27], have also been documented. Notably, REST4
with ZFM-5 is transported to the nucleus while REST1 without
ZFM-5 is not [32], and it was later demonstrated that ZFM-5 is
essential for the nuclear targeting of REST [33].
In this study, we performed a comprehensive analysis of the AS
of REST pre-mRNA and examined its relevance to cancer. We
demonstrate that: 1) REST undergoes extensive AS across a gene
boundary now doubled by a novel last exon (E5), with numerous
coding and non-coding mRNAs being formed with a species- and
cell-type/tissue-specific expression; 2) numerous REST splice
variants, which are caused by various splicing patterns (e.g. exon
skipping and alternative usage of the first and last exons) predictive
of altered REST activity, are generally but differentially linked to
various types of cancer; and 3) exon 3 (E3) skipping, which causes
no frame shift but loss of ZFM-5 essential for nuclear transloca-
tion, is remarkably affected by pioglitazone, a highly selective
agonist for PPARc which modulates cell differentiation and
tumorigenesis besides its metabolic actions. These findings
advance our understanding of the complexity of REST gene
regulation and function, and provide potential biomarkers and
therapeutic targets for cancer.
Materials and Methods
Ethics Statement
The use of human tissues was approved by the Harvard
Institutional Review Board, and the related projects for which
macaques and mice were euthanized were approved by the
Institutional Animal Care and Use Committee for Harvard
Medical School. The Harvard Medical School animal manage-
ment program is accredited by the American Association for the
Accreditation of Laboratory Animal Care (AAALAC) and meets
National Institutes of Health standards as set forth in the Guide for
the Care and Use of Laboratory Animals (DHHS Publication No.
(NIH) 85–23 Revised 1985). The institution also accepts as
mandatory the PHS Policy on Humane Care and Use of
Laboratory Animals by Awardee Institutions and NIH Principles
for the Utilization and Care of Vertebrate Animals Used in
Testing, Research, and Training.
Animals (macaques and mice) involved in this study were cared
for in compliance with National Institutes of Health, US
Department of Agriculture, and Harvard Medical School guide-
lines for animal research. Macaques were single-housed and all
efforts were made to reduce discomfort and provide enrichment
opportunities (e.g. varied food supplements, foraging and task-
oriented feeding methods, and interaction with caregivers and
research staff). Specifically, macaques were fed twice daily (AM
and PM) with a balanced commercially available Old World
Primate Diet (e.g. Harlan Teklad 8714 Monkey Diet). Fruit and/
or vegetable supplements were provided to all animals daily, and
drinking water was provided ad libitum by automatic water lixits
or plastic water bottles. Tissue samples were collected from five
macaques which had been utilized in other experiments at the
time of their necropsy. The macaques were euthanized following
being anesthetized with ketamine HCl by an intravenous
pentobarbital overdose, and exsanguinated. Mice were euthanized
with carbon dioxide gas inhalation followed by cervical disloca-
tion, and all efforts were made to minimize suffering.
Human and animal tissues
The cDNA samples derived from adult normal human tissues
(kidney, liver, lung, pituitary, hippocampus, amygdala and pons, 1
for each) were purchased from the BioChainH Institute, Inc
(Newark, CA). 27 pairs of tumor and adjacent normal tissues from
patients diagnosed clinically with kidney, liver and lung cancers (9
pairs for each) were obtained from the UMass Cancer Center
Tissue Bank (5 pairs for each cancer as tissue in RNAlater) and the
BioChainH Institute Inc (4 pairs for each cancer as total RNA).
The demographic information of the patients briefly shown in
Table 1. The human peripheral blood mononuclear cells
(PBMCs), which were purified as described previously [34], were
kindly gifted by Dr. Fred Wang at the Brigham & Women’s
Hospital. We also collected tissues from rhesus monkeys and mice
euthanized for other projects.
Cell lines and drug treatment
A total of 18 cell lines derived from human (HEK293,
HEK293T, HepG2, NCCIT, SH-SY5Y, A549, MCF7, K562,
SK-N-MC, HeLa, Raji, TE671, Jurkat, Sup-T1 and induced
pluripotent stem (iPS)), nonhuman primate (COS-7) and rodents
(RN46A and PC12) were employed in this study. Except for
RN46A and iPS, all the other 16 cell lines were obtained from
American Type Culture Collection (Manassas, VA). RN46A cells
were kindly provided by Dr. Scott Whittemore [35], while the iPS
cells were originated from Dr. Stephen J. Haggarty [36]. To
examine the effect of pioglitazone on REST pre-mRNA splicing,
the NCCIT, HEK293T and HepG2 cells were treated with either
10 mM of pioglitazone (Sigma-Aldrich) or a matched concentra-
tion of the solvent (0.04% DMSO), and cells were harvested at
48 hours following treatment. Treatments were performed in
duplicate on 3 independent occasions.
RNA isolation and cDNA synthesis
Total RNA was extracted using TrizolH reagent (Invitrogen).
An aliquot of total RNA was reverse transcribed into cDNA using
the QuantiTectH Reverse Transcription Kit (Qiagen), while
another aliquot was reverse transcribed into cDNA by using an
anchored oligo-dT (anchor sequence given in Table 2). Synthe-
sized cDNA was diluted to 50 ng/ml for use.
PCR amplification and DNA sequencing
A touchdown PCR protocol was employed for both standard
and nested PCRs, and amplifications were performed in a MJ
Research PTC-200 Peltier Thermal Cycler (GMI) in a total
volume of 20 ml comprising 1 ml of template (50 ng/ml cDNA for
standard or 1
st step PCR, and 1:20 diluted product of 1
st step PCR
for 2
nd step of nested PCR), 10 pmoles of each primer (Table 2),
and 10 ml of GoTaqH Green Master Mix (Promega). The first step
of nested PCR was performed by using cDNA made by anchored
oligo-dT as template and oligo-dT anchor paired with E1aF2,
E1bF2 and E1cF2 as the primer sets. For adult normal human
tissues without cDNA made by anchored oligo-dT available, the
oligo-dT anchor was replaced by E4R3 and E5R2 (outside E4R1
and E5R1, respectively). Primers for rhesus macaque and rodents
REST Pre-mRNA Splicing and Cancer
PLOS ONE | www.plosone.org 2 April 2013 | Volume 8 | Issue 4 | e62217were modified if necessary. Amplification conditions involved an
initial 2.5 min denaturation at 95uC, followed by 28 (for 1
st step of
nested PCR) or 40 (for standard or 2
nd step of nested PCR) cycles
of 30 s denaturation at 95uC, 30 s annealing (temperature starting
at 61uC and decreased by 0.5uC/cycle for the initial 12 cycles,
then fixed at 55uC), and 60,180 s extension at 72uC, with a final
extension of 5 min at 72uC. PCR products were loaded on a 2%
agarose gel and amplicons of distinct size were excised, purified
and sequenced. DNA sequencing was performed as commercial
service by the Functional Biosciences Inc (Madison, WI). PCR
products with poor quality sequencing data were cloned into
pGEMH-T vector (Promega) for further sequencing.
59/39 Rapid amplification of cDNA ends (RACE)
Total RNA generated from HEK293, HEK293T, HepG2 and
SH-SY5Y were used to perform the 59 and 39 RACE, which were
carried out by two commercial kits, the 59/39 RACE Kit (2
nd
Generation) from Roche (Indianapolis, IN) and GeneRacerH from
Invitrogen, which differ in strategies for 59 RACE. For 59 RACE
with GeneRacerH kit, a RNA Oligo was firstly ligated to RNA,
followed by cDNA synthesis using Oligo-dT and nested PCR
using REST-specific reverse primers (e.g. E4R1 and E4R2) paired
with a GeneRacerH 59 primer (homologous to the RNA Oligo).
For 59 RACE with Roche’s kit, cDNA was first synthesized from
total RNA using a REST-specific reverse primer (e.g. E4R2,
outside), followed by tailing with dATP and terminale transferase
and subsequent nested PCR using anchored Oligo-dT or anchor
primer paired with a REST-specific reverse primer (e.g. E4R1,
Table 1. Demographic data for the patients with cancer.
ID# Gender Age(y) Basic Diagnosis Grade
Kidney cancer
Ki#1 Male 2 Nephroblastoma n.a.
Ki#2 Male 45 Renal Cell Carcinoma 2
Ki#3 Male 43 Renal Cell Carcinoma 2
Ki#4 Female 50 Renal Cell Carcinoma 2
Ki#5 Male 52 Renal Cell Carcinoma 2
Ki#6 Female 75 Renal Cell Carcinoma 2
Ki#7 Male 53 Renal Cell Carcinoma n.a.
Ki#8 Male 63 Renal Cell Carcinoma n.a.
Ki#9 Female 55 Adenocarcinoma n.a.
Liver cancer
Li#1 Male 59 Hepatocellular Carcinoma 3
Li#2 Male 59 Hepatocellular Carcinoma n.a.
Li#3 Female 71 Hepatocellular Carcinoma 3
Li#4 Male 58 Cholangiocarcinoma 2
Li#5 Male 59 Cholangiocarcinoma 2
Li#6 Female 36 Cholangiocarcinoma 2
Li#7 Male 60 Hepatocellular Carcinoma n.a.
Li#8 Male 33 Hepatocellular Carcinoma n.a.
Li#9 Male 47 Hepatocellular Carcinoma n.a.
Lung cancer
Lu#1 Male 51 Adenocarcinoma 3
Lu#2 Male 63 Squamous Cell Carcinoma n.a.
Lu#3 Male 64 Adenocarcinoma 3
Lu#4 Male 51 Adenocarcinoma 3
Lu#5 Male 61 Adenocarcinoma 3
Lu#6 Male 63 Adenocarcinoma (100%) 3
Lu#7 Male 46 Squamous cell carcinoma n.a.
Lu#8 Male 63 Squamous cell carcinoma n.a.
Lu#9 Male 67 Squamous cell carcinoma n.a.
Note: The grade information is not available for samples from BioChain
H
Institute, Inc.
doi:10.1371/journal.pone.0062217.t001
Table 2. Oligos used for the detection of specific REST splice
variants.
Name Sequence Note
Standard/nested PCR
*E1aF1 59-cgaaactccagcaacaaaga-39
E1aF2 59-ccagcacccaactttaccac-39
*E1bF1 59-agaagcccggacgccggct-39
E1bF2 59-tcggagaagcccggacgc-39
*E1cF1 59-gatggcatttgcttccaact-39
E1cF2 59-cctggacggtcttcctaaca-39
E2F1 59-cagtgagcgagtatcactgga-39
E4R1 59-ctgcactgatcacatttaaatg-39
E4R2 5’-caaactaagaactgaaaccttgttca-39
E4R3 59-cacataactgcactgatcacattta-39
E5R1 59-ccctgtgcatatcacctcct-39
E5R2 59-agggaaatcagtcagcttgg-39
rhesus-E1aF2 59-ccagcacccaacttttccac-39
rhesus-E4R3 59-cacgtaactgcactgatcacattta-39
mouse-E1aF2 59-cctcgacgcccaacttttcc-39
mouse-E4R3 59-cacataattgcactgatcacattta-39
rat-E2F1 59-cagtcagcgaataccactggc-39
rat-E5R1 59-tgtggcttccaacttccttc-39
rat-E5R2 59-agggaaatcaatcagcctgg-39
*E2R1 59-tggaaaggtcatgcaagtca-39
E2R2 59-atggaacctggatttgaacc-39
Oligo-dT anchor 59-gaccacgcgtatcgatgtcgac-39
qRT-PCR
E1a/E3-F 59-cgaggaaggccggagaac-39 SYBR Green I
E1a/E3-R 59-gcccattgtgaacctgtctt-39
E1a/E4-F 59-gaggaaggccggtgagaa-39 SYBR Green I
E1a/E4-R 59-cgtgggttcacatgtagctct-39
E1a/E2-#43F 59-cgaggaaggccgaataca-39 Hybridization Probe
E1a/E2-#43R 59-agccctcctcctccagaa-39
E1c/E2-#43F 59-tctgtgatggcatttgcttc-39 Hybridization Probe
E1c/E2-#43R 59-gttgccactgctggtaaaca-39
E3/E5-#88F 59-gacatatgcgtactcattcagagc-39 Hybridization Probe
E3/E5-#88R 59-ttggtttacagtcgtggcttc-39
E2-F1 59-accgaccaggtaatcacagc-39 SYBR Green I
E2-R1 59-ctggtgtggtgtttcaggtg-39
GAPDH-F1 59-tgccctcaacgaccactttg-39 SYBR Green I
GAPDH-R1 59-tctctcttcctcttgtgctcttgc-39
*The E1a/E2,E 1b/E2,E 1c/E2 junctions can be quantified by SYBR Green I qRT-PCR
using the E1aF1,E 1bF1 and E1cF1 paired with E2R1, respectively.
doi:10.1371/journal.pone.0062217.t002
REST Pre-mRNA Splicing and Cancer
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RNA using anchored Oligo-dT, followed by nested PCR using
REST-specific forward primers (e.g. E1aF1 and E1aF2) paired with
the anchor primer.
Quantitative real-time PCR (qRT-PCR) assay
Using primers listed in Table 2, we developed SYBR Green I
and/or Hybridization Probe qRT-PCR for specific exon-exon
junctions and exon 2 (E2, presumably represents overall expression
of coding mRNAs regardless of the first and last exons), as well as
the housekeeping gene GAPDH. The qRT-PCR assays were
performed as previously described on a Roche LightCycler 2.0
system [37], with the threshold cycle (Ct) values being employed to
evaluate the expression change between paired tissues or cells by
the 2
2DDCt approach [38]. PCR reactions were run in duplicate.
For E1a/E4 junction which is expressed at low levels in most cases,
only SYBR Green I assay is available and the Ct values are likely
confounded by primer dimer formed by excessive remaining
primers, so we performed qRT-PCR by using the product of the
1
st step PCR as template. Owing to the high sequence identity
between the 39 ends of E2 and E3, qRT-PCR assay specific for E2/
E4 junction was not attainable.
Bioinformatics and data analysis
Prediction of the open reading frame (ORF) of specific REST
variants was performed by using the StarORF program (http://
star.mit.edu/orf/runapp.html), and epigenetic information at the
REST locus was retrieved from the UCSC Genome Browser
(http://genome.ucsc.edu/cgi-bin/hgGateway). Comparisons of
qRT-PCR-assayed expression levels of specific exon-exon junc-
tions between paired tissues or cells were carried out by the 2
2DDCt
approach using appropriate reference, and two-fold change was
considered as significant.
Results
Identification of E2/E3 skipping expressed in a species-
dependent manner
We performed standard and nested PCRs with cDNA samples
derived from numerous human tissues (liver, kidney, lung,
pituitary, hippocampus, amygdala and pons) and cell lines
(HEK293, HEK293T, HepG2, NCCIT, SH-SY5Y, A549,
MCF7 and iPS). Using a reverse primer E4R1 targeting the
proximal exon 4 (E4) paired with the forward primers E1aF1 and
E2F1 targeting exons 1a (E1a) and 2 (E2) (Figure 1A and Table 2),
respectively, we identified several REST splice variants with E2
and/or E3 skipped (Figure 1B and 1C). The variant with E2
skipped is abundantly expressed in all tested cell lines and tissues
except amygdala, while the variants with E3 alone or plus E2
skipped were expressed at low levels in a subset of tissues and cell
lines. Notably, E2/E3 skipping is predominantly associated with
E1a but rarely with E1b and E1c (Figure 1B). In addition, E2/E3
skipping was observed in another 7 human cell lines and the
peripheral blood mononuclear cells (PBMCs) (Figure S1).
We tested whether E2/E3 skipping is expressed in nonhuman
primate and rodent tissues and cell lines. As shown in Figure 1D,
skipping of E2 alone was only observed in amygdala and pineal out
of 17 tissues obtained from 1 rhesus macaque, while skipping of
both E2 and E3 was only observed in macaque PBMCs and COS-
7 cells (derived from African green monkey kidney); however,
skipping of E3 alone was observed in most macaque tissues and
COS-7 cell line. In rodents, skipping of E2 (alone and plus E3) was
observed in RN46A but not PC12 cells, while skipping of E2 alone
was observed in the hippocampus from 2 of 4 mice tested,
suggesting an inter-individual difference. Similarly, individual
difference in REST pre-mRNA splicing was also observed in the
pons and raphe from 4 macaques (Figure S2).
Discovery of a novel last exon which doubles human
REST gene boundary
We performed RACE to determine the 59 and 39 ends of human
REST mRNA. Unexpectedly, we identified a novel polyadenylated
exon (E5) that locates ,30 kb downstream of E4 and partially
overlaps in opposite direction with exon 5 of the nitric oxide
associated-1 (NOA1) gene (Figure 2A), which encodes a GTPase
essential for mitochondrial protein synthesis [39]. By nested PCRs
using an E5-specific reverse primer (E5R1) paired with E1aF1 and
E2F1, respectively, we found that E5 inclusion, occasionally in
combination with E2/E3 skipping, is expressed in most human
tissues and cell lines (Figure 2B, 2C and Figure S1). Like E2/E3
skipping, E5 inclusion is primarily associated with E1a but rarely
with E1b and E1c. Notably, we found no variants containing both E4
and E5, suggesting that E4 and E5 are mutually exclusive and that
E4, like the case for E2 and E3, can be completely skipped.
Accordingly, the novel last exon E5 doubles the human REST gene
boundary from ,28 kb to ,59 kb (Figure 3A). E5 inclusion was not
observed in nonhuman primates and rodents.
Extensive AS of REST pre-mRNA
By examining above-mentioned primate tissues and cell lines, as
well as paired tumor and adjacent normal tissues from cancer
patients mentioned hereinafter, we revealed an extensive AS of
REST pre-mRNA. As shown in Figure 3A, besides E5 and the
previously reported exon N (now renamed as N3c), we identified
another 7 novel alternative exons (N1,N 2a,N 2b,N 3a,N 3b,N 4a and
N4b), along with numerous 59/39 SS and ends in the constitutive
exons E2 and E4. Regardless of the 59/39 ends in E2 and E4,a t
least 45 variants (S1–S45) are formed by various splicing patterns
including exon skipping, alternative 59/39 SS, mutual exclusion
and alternative usage of the first and last exons (Figure 3B).
Sequences of the novel variants have been deposited in GenBank
with assigned accession numbers JX896957-JX896993 and
KC117262-KC117266.
29 of the 45 splice variants involve full or partial skipping of E2
where translation initiates, such that they may function as ncRNAs
due to lack of the translation start site (TSS), except that several
variants (S16, S19 and S28) whose TSS was preserved are
predictive of N-terminal truncated REST protein isoforms.
Similarly, partial or complete skipping of E4, which is frequently
accompanied by E2 skipping and/or E5 inclusion, produces
numerous ncRNAs or coding mRNAs predictive of truncated
REST protein isoforms. In contrast, skipping of the 84-bp E3 (S4
and S34) causes no frame shift but loss of ZFM-5. Notably,
variants with intact E2 (or plus E3) followed by alternative exons
(but not E4) are predicted to encode C-terminal truncated REST
proteins, of which 8 variants with E3 encode REST4 (S3 and S12)
or REST4-like (S2, S21, S31, S33, S39 and S41) proteins with
RD1 and ZFMs 1–5, while another 4 variants (S34, S39–S41) with
E3 skipped encode REST1 with RD1 and ZFMs 1–4 (Figure 3C).
Most of the 45 splice variants are expressed at low levels in a
cell-type/tissue-specific manner; however, at least one variant was
observed in all the tested tissues and cell lines (Figure 1, 2 and
Figure S3).
Link between REST pre-mRNA splicing and cancer
We compared the expression of specific splicing patterns and
variants between paired tumor (T) and adjacent normal (N) tissues
REST Pre-mRNA Splicing and Cancer
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(9 pairs for each cancer, Table 1) by nested PCR and qRT-PCR
assays, with a focus on E2/E3 skipping and alternative usage of the
first and last exons. The qRT-PCR assays were designed targeting
specific exon-exon junctions (Figure 4A), and expression changes
of specific splicing between T and N are shown in folds (T over N)
for each subject (Figure 4B). With the exception of E1a/E3 and
E1a/E4 which represent S5 and S6 variants, respectively, the exon-
exon junctions do not necessarily represent a single specific splice
variant, which however can be detected by nested PCRs
(Figure 4C). Accordingly, both qRT-PCR and nested PCR assays
were taken into consideration for the comparison of REST pre-
mRNA splicing profile between paired T and N tissues. While the
wide expression of E2/E3 skipping and E5 inclusion in human was
further validated, we found that all the 27 patients without
exception showed differential expression of numerous REST splice
variants caused by specific splicing patterns between paired T and
N tissues, with a striking tissue-type and individual difference.
As shown in Figure 4B and 4C, variants with E2/E3 skipped
were differentially expressed between paired T and N tissues for
most patients. Of variants using E4 as the last exon, S6 (both E2
and E3 skipped) showed strikingly differential expression for all the
patients except Lu#4 and 7. Specifically, 7, 5 and 1 patients with
kidney, liver and lung cancer, respectively, showed increased S6
expression, whereas 2, 4 and 6 patients with kidney, liver and lung
cancer, respectively, exhibited decreased S6 expression. Although
qRT-PCR assay for E3 skipping only (i.e. E2/E4 junction) is not
attainable, nested PCR with E2F1/E4R1 showed apparently
Figure 1. Schematic structure of REST gene and identification of E2/E3 skipping. (A) Illustration of annotated REST exons and locations of
primers employed for the identification of REST splice variants. The constitutive exons (1a, 2, 3 and 4) and alternative exons (1b, 1c and N) are shown
in open and gray boxes, respectively, while the forward and reverse primers are indicated by right and left arrows, respectively. (B) Detection of E2/E3
skipping in human tissues and cell lines by nested PCRs with specific primer sets. E2/E3 skipping is commonly associated with E1a but rarely associated
with E1b and E1c.( C) Trace chromatograms for exon-exon junctions involved in E2/E3 skipping. (D) Detection of E2/E3 skipping in tissues and cell lines
from nonhuman primates and rodents by nested PCR. Of the numerous rhesus tissues, E2 skipping alone was only observed in amygdale (a) and
pineal (b).
doi:10.1371/journal.pone.0062217.g001
REST Pre-mRNA Splicing and Cancer
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of patients. Meanwhile, differential expression of E2-skipped
variants S5 and S15 between paired T and N from some patients
was shown by qRT-PCR and nested PCR, respectively. Moreover,
some other variants (e.g. S14, S16 and S17) with E1b as the first
exon and E2 partially skipped were differentially expressed
between paired T and N for a few patients. For example, S14
and S16 were only observed in the T tissues of 4 patients (Ki#5, 6
for S14 and Ki#4, Lu#9 for S16, respectively). Likewise, of
variants using E5 as the last exon, S34 (E3 skipped), S35 (E2
skipped) and S38 (both E2 and E3 skipped) showed apparently
differential expression between paired T and N as indicated by
nested PCRs with E1aF1/E5R1 and E2F1/E5R1. Accordingly, E2/
E3 (especially E3) skipping is generally but differentially linked to
different types of cancer with striking cell-type/tissue and
individual differences.
As shown in Figure 4C, with the exception of 3 patients (Li#5,
6 and Lu#6) without detectable expression of E5 inclusion, all
other patients showed differential expression of E5-included
variants between paired T and N tissues. Particularly, the
expression of S33/S39 without E2/E3 skipping was gained and
lost in the T tissues of 6 (Ki#2, 9, Li#1, 3, 7 and Lu#3) and 4
(Ki#1, 4, 7, 8 and Lu#1) patients, respectively. Notably, nested
PCR with E2F1/E5R1 showed that all 9 kidney cancer patients
expressed E5 in their N tissues, of them 3 (Ki#1, 7, 8) lost E5
expression in their T tissues. By contrast, all 9 patients with liver
cancer showed no E5 expression in their N tissues, and of them, 4
(Li#1, 2, 3, 7) gained E5 expression in their T tissues. The
differential expression of E5-included variants between paired T
and N tissues shown by nested PCR was supported by qRT-PCR
assay of E3/E5 junction (Figure 4B).
In addition, the variant S18 which uses E1c as the first exon was
differentially expressed between paired T and N tissues for most
(22/27) patients, with 12 and 10 patients showing increased and
decreased expression, respectively (Figure 4B and 4C). Meanwhile,
qRT-PCR assay indicated that the variants S1 and S11 which use
E1a and E1b as the first exon, respectively, showed greater than 2-
fold expression changes between paired T and N tissues for some
patients (Figure 4B). Accordingly, alternative usage of the first
exon (especially E1c) was differentially linked to different types of
cancer.
Regulation of E3 skipping by the selective PPARc
activator pioglitazone
A view of the UCSC Genome Browser (http://genome.ucsc.
edu/cgi-bin/hgGateway) indicates that E3 of REST contains a
conserved binding motif for the peroxisome proliferator-activated
receptor gamma (PPARc) (Figure 5A), a ligand-activated nuclear
receptor that contributes to cell differentiation and tumorigenesis
besides its metabolic actions [40,41]. Intriguingly, in searching for
environmental factors that affect REST pre-mRNA splicing, we
found that pioglitazone, a highly selective PPARc agonist, exerts a
cell-dependent effect on E3 skipping (Figure 5B-D). In NCCIT, a
pluripotent stem cell line derived from human embryonic
carcinoma, pioglitazone (10 mM) strikingly induced E3 skipping
as indicated by increased expression of E3-skipped variants (S4 and
S6) and decreased expression of E3-included variants (S1 and S5).
In contrast, pioglitazone (10 mM) slightly reduced E3 skipping in
HepG2 cells while it exerted no effect on E3 skipping in HEK293T
cells.
Discussion
We reveal that REST undergoes extensive AS across an
unexpectedly large gene boundary defined by a novel alternate
last exon (E5), with numerous ncRNAs and coding mRNAs being
expressed in a species- and cell-type/tissue-specific manner with
individual differences. Notably, we found that exon (E2,E 3 and E4)
skipping is preferentially associated with the usage of the
conventional E1a as the first exon, i.e., AS of REST pre-mRNA
Figure 2. Identification of a novel last exon (E5)o fREST. (A) Sequence of E5 and its partial (81-bp) overlapping with NOA1 gene in opposite
direction. (B) Detection of E5 inclusion in human tissues and cell lines by nested PCR. (C) Trace chromatograms for junctions of E5 with E1a,E 2 and E3.
Note that the 39 ends of E2 and E3 share high sequence identity.
doi:10.1371/journal.pone.0062217.g002
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differ not only in the strength, but also in transcription elongation
which is a major determent of pre-mRNA splicing. Since most
splice variants involve a complete or partial skipping of exons (e.g.
E2,E 3 and E4) encoding specific functional domains of REST,
their functional significance is generally predictable. Accordingly,
these alternatively spliced REST variants, which are mostly
expressed in a cell-type/tissue-specific manner with individual
differences, presumably contribute to the diverse, context-depen-
dent regulation of REST gene expression. Notably, we found that
all tissues and cell lines without exception express at least one
REST splice variant, and no apparent difference in the expression
pattern of specific splice variants was observed between neuronal
and non-neuronal tissues. In agreement, similar levels of the initial
REST transcripts were reported between neuronal and non-
neuronal cells [42], while the promoter of REST exhibits cell-type-
independent active transcription as indicated by publically
available epigenetic data (Figure 6), suggesting that transcriptional
regulation is unlikely a major contributor to cell-type/tissue-
specific expression of REST. Hence, in line with epigenetic
regulation of AS and the emerging role of AS in adaptive
responses [2,6], our findings strongly suggest that pre-mRNA
splicing, rather than transcription regulation, substantially con-
tributes to the diverse, context-dependent REST gene expression
and function.
REST functions as a tumor suppressor or an oncogene
depending on cellular context, with both increased and decreased
REST activity having been reported in different types of cancer
[18,19]. In accordance, we found that numerous REST splice
variants produced by E2/E3 skipping and alternative usage of the
Figure 3. Details of the identified REST exons, splicing patterns and resultant splice variants. (A) Identified REST exons and their 59/39 SS
or ends. The UCSC genes track was used to briefly indicate the chromosomal location of REST gene locus, while the genomic sequence NG_029447
was employed as a reference to clarify the exact positions of the exons. Major domains of the REST protein (NP_005603) were illustrated parallel to
the corresponding coding region so as to predict consequences of the AS of REST pre-mRNA at the protein level. The constitutive and alternative
exons, as well as their 59/39 SS or ends, are color-coded as indicated. Note that: 1) exon N in Figure 1 is renamed as N3c here; 2) E2k is an extension of
E2a without splicing; and 3) E5 and N4b are not actually presented in NG_029447. (B) Patterns of REST pre-mRNA splicing and resultant mRNA variants.
Putative coding variants are color-coded (blue–no amino acid change predicted; red-truncated protein) or shadowed (loss of ZFM-5). (C) Prediction of
C-terminal truncated REST proteins for specific mRNA variants. The exon-exon junctions and premature stop codons are underlined.
doi:10.1371/journal.pone.0062217.g003
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are generally but differentially linked to different types of cancer.
Particularly, in accordance with the involvement of REST4 and
another C-terminal truncated REST-FS (caused by a frameshift
mutation) in tumorigenesis [26–28,43], we found that the usage of
E5 as the last exon, which is predictive of a C-terminal truncated
REST4-like protein, is differentially linked to various types of
cancer. Unlike REST4 which exists in both primates and rodents,
E5 inclusion is only expressed in human but it shows a wide tissue
distribution, suggesting that it may contribute to the pathophys-
iology of a wide spectrum of human diseases. Besides encoding a
REST4-like protein, E5-included variants overlap in opposite
direction with NOA1 transcript(s), i.e., transcripts of REST and
NOA1 act as natural antisense transcripts for each other, making it
possible that transcripts of one gene regulate expression of the
other gene through various mechanisms [44]. As a GTPase
essential for mitochondrial protein synthesis, NOA1 is involved in
oxidative stress and apoptosis [39,45,46]. Accordingly, E5
inclusion may mediate a coordinated effect of REST and NOA1
on cellular functions. In addition, E5 inclusion results in altered 39-
UTR, which contributes to posttranscriptional regulation (e.g.
mRNA stability) of gene expression.
Since E2 skipping eliminates the TSS, E2-skipped variants may
function as ncRNAs which potentially modulate REST gene
expression. Similar to E5 inclusion which is exclusively expressed
in human, E2 skipping is ubiquitously expressed in human but
rarely expressed in nonhuman primates and rodents, suggesting
that human evolution involves a gain of much more complex
REST pre-mRNA splicing, which may contribute to context-
dependent human genome function that is by far more complex
than other species. As for the E3 skipping, it causes no frame shift
but loss of ZFM-5 essential for nuclear translocation [32,33], such
that it provides an alternate mechanism for the regulation of
REST activity. Notably, while REST-5FD caused by E3 skipping
was only previously observed in SH-SY5Y cells [27], we revealed a
ubiquitous though usually non-abundant expression of E3 skipping
in primates, suggesting that E3 skipping might be a common
regulator which specifies the diverse, context-dependent function
of REST. In accordance, we found that numerous E3-skipped
variants were differentially expressed between paired tumor and
adjacent normal tissues for most patients with cancer, and that E3
skipping is modulated by the PPARc activator pioglitazone which
contributes to cell differentiation and tumorigenesis [40,41,47]. In
addition, our preliminary data showed that E3 skipping is linked to
Figure 4. Comparison of REST pre-mRNA splicing profile between paired tumor (T) and adjacent normal (N) tissues. (A) Strategy for
the design of qRT-PCR assay for specific exon-exon junctions. (B) Expression changes (T over N, in fold) of specific exon-exon junctions assayed by
qRT-PCR assay; (C) Expression of specific REST splice variants detected by nested PCR. The forward and reverse primers are indicated by right and left
arrows, respectively. Paired T and N tissues were collected from 27 patients with kidney (Ki), liver (Li) and lung (Lu), and the basic diagnosis shown in
Table 1 was briefly given as its initial 3 letters for each patient. Expression changes (T over N, in fold) of specific variants or splicing (e.g. exon-exon
junctions) were assayed by qRT-PCR and calculated by the 2
2DDCt approach using E2 as the reference. Data are shown as Mean6SEM. qRT-PCR assay
is not attainable for E3 skipping only (i.e. E2/E4 junction), but apparent changes can be observed between T and N tissues for most subjects by nested
PCR using the E2F1/E4R1 primer set.
doi:10.1371/journal.pone.0062217.g004
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and nonhuman primates (unpublished data). Hence, E3 skipping
represents a potential biomarker for cancer. With respect to the
alternative usage of the first exon, it alters the 59-untranslated
region which plays an important role in posttranscriptional
regulation (e.g. mRNA stability, targeting and translation) of gene
expression [37], such that it may affect the expression level of
REST protein.
It has been documented that REST is a prognostic factor and
therapeutic target for cancer [48,49]. Accordingly, correction of
aberrant REST pre-mRNA splicing provides a new strategy for the
treatment of cancer. Indeed, pioglitazone regulation of E3 skipping
strongly supports the feasibility of manipulating REST activity
through modulation of pre-mRNA splicing. Since E3 contains a
conserved binding motif for PPARc, it is likely that the binding of
activated PPARc to E3 interrupts the action of other splicing
Figure 5. The effect of the selective PPARc activator pioglitazone on REST E3 skipping. (A) Presence of an evolutionarily conserved PPARc
motif in REST E3. Bioinformatic data of the HMR Conserved Transcription Factor Binding Sites was retrieved from the UCSC Genome Browser (http://
genome.ucsc.edu/cgi-bin/hgGateway). Cell-specific effect of pioglitazone (10 mM) on the expression of REST variants with/without E3 skipping was
detected by standard PCR (B and C) and qRT-PCR (D). Standard PCR with E2F1/E4R1 showed that pioglitazone strikingly induced and slightly reduced
E3 skipping in NCCIT and HepG2 cells, respectively, but exerted no effect in HEK293T cells. Regulation of E3 skipping by pioglitazone in NCCIT can also
be observed by standard PCR with E1aF1/E4R1. Pioglitazone regulation of E3 skipping in NCCIT and HepG2 was further confirmed by qRT-PCR assay.
Expression changes (pioglitazone over DMSO) were calculated by the 2
2DDCt approach using GAPDH as the reference.
doi:10.1371/journal.pone.0062217.g005
Figure 6. Bioinformatics at the REST gene locus. Data are retrieved from the UCSC Genome Browser (http://genome.ucsc.edu/cgi-bin/
hgGateway). The REST promoter harbors a large-size CpG island and displays active transcription for all the 9 available cell lines without exception, as
indicated by the chromatin state segmentation and histone H3 lysine 27 acetylation (H3K27Ac) tracks.
doi:10.1371/journal.pone.0062217.g006
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first study reporting the regulation of pre-mRNA splicing by a
ligand of PPARc, which usually affects gene transcription [50].
PPARc is implicated in a wide variety of biological processes
including adipogenesis, glucose metabolism, inflammation and
tumorigenesis, and it is the molecular target of the thiazolidine-
dione (TZD) class of antidiabetic drugs including pioglitazone and
rosiglitazone [51]. It has been shown that TZDs suppress the
growth of several cancer lines in vitro and in vivo, and lines of
preclinical evidence supports the antineoplstic effects of PPARc
agonists; however, results from clinical trials show modest success
[52]. Recently, the use of pioglitazone for type 2 diabetes mellitus
is reportedly associated with an increased risk of bladder cancer
[53], suggesting a context-dependent, bidirectional effect of
PPARc on tumorigenesis, which is in accordance with its cell-
specific effect on E3 skipping (Fig.5), as well as the notion that both
decreased and increased REST activity may contribute to
tumorigenesis [18,19]. Mechanism(s) by which PPARc modulates
tumorigenesis are not yet fully understood; however, based on the
role of REST in tumorigenesis and the regulation of REST activity
by E3 skipping, we speculate that PPARc regulation of REST pre-
mRNA splicing is attributable. Accordingly, the context-depen-
dent REST activity modulated by E3 skipping may underlie the
context-dependent effect of PPARc on tumorigenesis, such that E3
skipping represents a potential therapeutic target that might be
utilized for personalized medicine for cancer. Moreover, REST
targets numerous genes involved in metabolism [54], suggesting
that PPARc regulation of REST pre-mRNA splicing may
contribute, at least in part, to the metabolic actions of PPARc.
In this regard, this study provides a novel mechanism underlying
the biological actions of PPARc and the close link between
metabolism and tumorigenesis [55]. Furthermore, PPARc exerts a
neuroprotective effect on neurodegenerative disorders including
Huntington disease, which is caused by disassociation of mutant
Huntingtin protein with REST in the cytoplasm and therefore
enhanced nuclear translocation and aberrant accumulation of
REST in nucleus [21,56,57]. It is tempting to speculate that the
neuroprotective effect of PPARc might be explained by its
regulation of E3 skipping (presumably increased in neurons),
which may result in reduced translocation of REST into the
nucleus and alleviation of the repressive effect of REST on
neuronal genes essential for the maintenance of neurons. Thus, E3
skipping may have implications for a wide variety of human
diseases.
In summary, this study revealed an extensive AS of REST pre-
mRNA and a close link between aberrant REST pre-mRNA
splicing and various types of cancer. The findings not only
advance our understanding of the complexity of REST gene
expression and function, but also provide potential biomarkers and
therapeutic targets for the diagnosis and individualized treatment
of cancer. However, our findings require further validation in a
large population of patients with different types and prognosis of
cancer, and warrant further investigation of mechanisms under-
lying REST pre-mRNA splicing regulation and biological func-
tions of specific REST splice variants.
Supporting Information
Figure S1 Detection of E2/E3 skipping and E5 inclusion
in additional human cell lines and PBMCs. Nested PCRs
were performed by using the forward primers E1aF1 and E2F1
paired with the reverse primers E4R1 and E5R1, respectively.
(TIF)
Figure S2 Individual difference in REST E2 skipping in
rhesus monkeys. The primer set E1aF2/E4R1 was employed
to perform the standard PCR using cDNA samples from pons and
raphe tissues from 4 rhesus monkeys. E2 skipping was observed in
1 of the 4 macaque pons and raphe tissues, respectively.
(TIF)
Figure S3 Expression profile of REST splice variants in
human cell lines. The abundance of the expression was briefly
estimated by the band of standard/nested PCRs and was color-
encoded as indicated. The tissue distribution was given for variants
(S9, S10, S14-S16, S24, S30, S36 and S41) that were not detected
in cell lines. The glioblastoma tissue was obtained from UMass
Cancer Center Tissue Bank. The GenBank accession numbers are
given for 42 of the 45 variants.
(TIF)
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